How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

229 results for

Drug-induced Photosensitivity

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

21. Drug-induced subacute cutaneous lupus erythematosus associated with nab-paclitaxel therapy Full Text available with Trip Pro

Drug-induced subacute cutaneous lupus erythematosus associated with nab-paclitaxel therapy Drug-induced lupus erythematosus (dile) syndromes are documented complications of chemotherapeutic agents, including paclitaxel. Subacute cutaneous lupus erythematosus (scle) is a distinct dile syndrome presenting with characteristic annular or papulosquamous skin lesions in a photosensitive distribution with associated high anti-ssa titres. Previously, dile syndromes complicating paclitaxel therapy have (...) been attributed to polyethoxylated castor oil (Kolliphor EL: BASF, Ludwigshafen, Germany), the biologic solvent included in the drug's original formulation (Taxol: Bristol-Myers Squibb, Montreal, QC), rather than the parent chemotherapy molecule. Here, we report a characteristic case of drug-induced scle complicating treatment with nanoparticle albumin bound (nab)-paclitaxel (Abraxane: Celgene, Summit, NJ, U.S.A.), a solvent-free taxane formulation. The pertinent English-language literature is also

2013 Current Oncology

22. Drug-induced Photosensitivity

Drug-induced Photosensitivity Drug-induced Photosensitivity Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Drug-induced (...) Photosensitivity Drug-induced Photosensitivity Aka: Drug-induced Photosensitivity , Photosensitizer , Medication Causes of Phototoxic Reaction , Phytodermatitis , Phytophotodermatitis From Related Chapters II. Background Drugs below are Photosensitizers Skin reactions secondary to Photosensitizers III. Signs Linear or drip pattern of erythema or inflammation May follow pattern of Photosensitizer contact with skin (e.g. lime or lemon) in well demarcated area (contact with Photosensitizer) Early Erythema Pain

2015 FP Notebook

23. Drug-induced skin diseases. Full Text available with Trip Pro

Drug-induced skin diseases. 155489 1979 07 25 2018 11 13 0007-1447 1 6168 1979 Apr 07 British medical journal Br Med J Drug-induced skin diseases. 935-7 Hardie R A RA Savin J A JA eng Journal Article England Br Med J 0372673 0007-1447 AIM IM Drug Eruptions etiology Drug-Related Side Effects and Adverse Reactions Erythema chemically induced Humans Photosensitivity Disorders chemically induced Pigmentation Disorders chemically induced Skin Diseases chemically induced diagnosis drug therapy Skin

1979 British medical journal

24. The frequency of photosensitizing drug dispensings in Austria and Germany: A correlation with their photosensitizing potential based on published literature. Full Text available with Trip Pro

The frequency of photosensitizing drug dispensings in Austria and Germany: A correlation with their photosensitizing potential based on published literature. Drug-induced photosensitivity refers to the development of cutaneous adverse events due to interaction between a pharmaceutical compound and sunlight. Although photosensitivity is a very commonly listed side effect of systemic drugs reliable data on its actual incidence are lacking so far.A possible approach to evaluate the real-life (...) extent of drug-induced photosensitivity would be an analysis of the frequency of exposure to a given photosensitizing drug combined with an indicator of its photosensitizing potential. This could serve as a basis for developing a pharmaceutical 'heatmap' of photosensitivity.The presented study investigated the number of reimbursed dispensed packages of potentially photosensitizing drugs in Germany (DE) and Austria (AT) between 2010 and 2017 based on nationwide health insurance-based databases

2019 Journal of the European Academy of Dermatology and Venereology

25. Recent Developments in the Diagnosis and Management of Photosensitive Disorders. (Abstract)

Recent Developments in the Diagnosis and Management of Photosensitive Disorders. Photodermatoses occur in males and females of all races and ages. Onset can be variable in timing and influenced by genetic and environmental factors. Photodermatoses are broadly classified as immunologically mediated, chemical- and drug-induced, photoaggravated, and genetic (defective DNA repair or chromosomal instability) diseases. Advances in the field have led to improved recognition and treatment of many

2018 American journal of clinical dermatology

26. Systematic Review of Oral and Topical Botanicals in Reducing Photosensitivity Full Text available with Trip Pro

; 9(1): 57-63. doi: 10.1111/j.1087-0024.2004.00839.x 4. Moore DE. Drug-induced cutaneous photosensitivity: Inci- dence, mechanism, prevention and management. Drug safety. 2002; 25(5): 345-372. 5. Valbuena MC, Muvdi S, Lim HW. Actinic prurigo. Dermatol Clin. 2014; 32(3): 335-344. doi: 10.1016/j.det.2014.03.010 6. Crouch R, Foley P, Baker C. Actinic prurigo: A retrospec- tive analysis of 21 cases referred to an Australian photobiol- ogy clinic. Australas J Dermatol. 2002; 43(2): 128-132. doi (...) Systematic Review of Oral and Topical Botanicals in Reducing Photosensitivity DERMATOLOGY Open Journal http://dx.doi.org/10.17140/DRMTOJ-2-124 ISSN 2473-4799 Dermatol Open J Suzana Saric, BA 1 ; Ashley K. Clark, BS 1 ; Raja K. Sivamani, MD, MS, CAT 2,3* 1 School of Medicine, University of California – Davis, Sacramento, CA, USA 2 Department of Dermatology, University of California – Davis, Sacramento, CA, USA 3 Department of Biological Sciences, California State University – Sacramento, CA, USA

2017 Dermatology – Open Journal

27. Drug-Induced Generalized Skin Eruption in a Diabetes Mellitus Patient Receiving a Dipeptidyl Peptidase-4 Inhibitor Plus Metformin Full Text available with Trip Pro

Drug-Induced Generalized Skin Eruption in a Diabetes Mellitus Patient Receiving a Dipeptidyl Peptidase-4 Inhibitor Plus Metformin A generalized skin eruption with strong itching was induced by sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, in a patient almost 6 months after initiation of the drug. Physical examination revealed a spread of skin rash from chest to back, and abdomen and thigh. Discontinuation of the drug eliminated the skin rash immediately. The emergence of new rash (...) ended, and the rash itself withered after 1 week. The spread of the rash gradually shrank and the skin lesions subsided, leaving pigmentation 1 month later. Two months after cessation of sitagliptin, the skin eruption had subsided and oral steroid medication was stopped, but some small eczematous eruptions continued to appear intermittently. Although a drug-induced lymphocyte stimulation test was negative for sitagliptin, nonspecific radioimmunosorbent test for immunoglobulin E was increased to 532

2012 Diabetes Therapy

30. Pruritus

pruritus) 10 4.1.4 Pruritus in metabolic and endocrine diseases 11 4.1.5 Pruritus in malignancy 11 4.1.6 Pruritus in infectious diseases 12 4.1.7 Pruritus in neurological diseases 13 4.1.8 Pruritus in psychiatric diseases 14 4.1.9 Drug-induced chronic pruritus 14 4.2 Specific patient populations 15 4.2.1 Chronic pruritus in the elderly 15 4.2.2 Chronic pruritus in pregnancy 15 4.2.3 Chronic pruritus in children 16 5 Diagnostic management 178 5.1 Patient history and clinical examination 178 5.2 (...) (Lepping, Huber et al. 2015). Overall, the psychiatric population is little studied with regard to skin symptoms, but it is now established that psychiatric morbidity contributes to the pathophysiology of CP in the absence of skin disease (Pereira, Kremer et al. 2016). 4.1.9 Drug-induced chronic pruritus Drug-induced pruritus without visible skin lesions accounts for approximately 5% of adverse cutaneous reactions. Almost any drug may induce pruritus by various pathomechanisms (Table 2) (Reich, Stander

2019 European Dermatology Forum

32. Management of Atopic Eczema

%) Cream/Ointment Hydrocortisone Acetate 1% Cream/Ointment 1 - 2 times daily 1 - 2 times daily Worsening of untreated infection, contact dermatitis, perioral dermatitis, acne, depigmentation, dryness, hypertrichosis, secondary infection, skin atrophy, pruritus, tingling/stinging, rosacea, folliculitis, photosensitivity Moderate Betamethasone Valerate 1 in 2 dilution (0.05%) Cream/Ointment Betamethasone Valerate 1 in 4 dilution (0.025%) Cream/Ointment Clobetasone Butyrate 0.05% Cream/Ointment Untreated (...) Dipropionate 0.05% Cream/Ointment Betamethasone Valerate 0.1% Cream/Ointment Fluocinolone Acetonide 0.025% Cream Fluticasone Propionate 0.05% Cream Triamcinolone Acetonide 0.1% Cream 1 - 2 times daily 1 - 2 times daily Once daily Worsening of untreated infection, contact dermatitis, perioral dermatitis, acne, depigmentation, dryness, hypertrichosis, secondary infection, skin atrophy, pruritus, tingling/stinging, rosacea, folliculitis, photosensitivity Untreated bacterial, fungal or viral skin lesions

2019 Ministry of Health, Malaysia

34. Acne vulgaris: Oral antibiotics

with an increased risk of adverse effects such as drug-induced lupus, skin pigmentation and hepatitis. Macrolide antibiotics (such as erythromycin) should generally be avoided due to high levels of P. acnes resistance but can be used if tetracyclines are contraindicated (for example in pregnancy). A topical retinoid (if not contraindicated) or benzoyl peroxide should always be co-prescribed with oral antibiotics to reduce the risk of antibiotic resistance developing. Do not use topical and oral antibiotics (...) ), hepatic and renal impairment. For erythromycin — avoid in acute porphyria, caution is advised in renal impairment. Adverse effects For all tetracyclines — anorexia, anaphylaxis; angioedema; blood disorders; exfoliative dermatitis; hepatotoxicity and liver failure; hypersensitivity reactions; pancreatitis; pericarditis; photosensitivity; rash; Stevens-Johnson syndrome; urticaria, antibiotic-associated colitis; benign intracranial hypertension; diarrhoea; dysphagia; headache; nausea; oesophageal

2019 NICE Clinical Knowledge Summaries

35. Plitidepsin (Aplidin) - Multiple Myeloma

is photosensitive. Samples of plitidepsin were also exposed to stressed conditions (heat, acid, alkali and oxidative conditions). Samples were stable under dry and moist heat conditions, moderately stable under acidic and oxidative conditions, but degraded rapidly under aqueous alkaline conditions. The stability results indicate that the active substance manufactured by the proposed supplier is sufficiently stable. The stability results justify the proposed retest period of 48 months at 5 ± 3 ºC in the proposed (...) characteristics, plitidpesin is lyophilised with mannitol as a bulking agent. A mixture of water and t BuOH was suitable to dissolve both components and also facilitated the freeze-drying process. Plitidepsin is hygroscopic, photosensitive and degrades in basic aqueous media. It is however, sufficiently stable in acidic aqueous media and so a slightly acidic pH (4-7.5) is stipulated for the infusion solution. The bulk plitidepsin was shown to be both physicochemically and microbiologically stable for up to 24

2018 European Medicines Agency - EPARs

36. Prasugrel besilate (Prasugrel Mylan) Acute Coronary Syndrome, Unstable Angina, Myocardial Infarction

have been demonstrated to be reliable and stability indicating. A photostability study has been performed on one commercial scale batch of Prasugrel film-coated tablets according to ICH Q1B Guideline. The following parameters were tested: description, assay, dissolution, water (KF) and degradation products. The obtained stability results indicated that there are no out of specification results and thus, it can be concluded that Prasugrel film-coated tablets are not photosensitive. Forced

2018 European Medicines Agency - EPARs

38. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy Full Text available with Trip Pro

) test, SS-A/Anti-Ro, and SS-B/Anti-La if the rash is predominantly photodistributed or demonstrating photosensitivity. Consider expanding serologic studies or diagnostic work-up if other autoimmune conditions are considered. Skin biopsy, clinical photography may be performed when indicated. Review full list of patient medications to rule out other drug-induced cause for photosensitivity. Recommendation 1.1b – Management. It is recommended that clinicians manage grade 1 toxicities as follows: Should (...) ). Assess for lymphadenopathy, facial or distal extremity swelling (may be signs of drug-induced hypersensitivity syndrome [DIHS]/drug reaction with eosinophilia and systemic symptoms [DRESS]). Assess for pustules or blisters or erosions in addition to areas of “dusky erythema,” which may feel painful to palpation. To assess for a positive Nikolsky sign, place a gloved finger tangentially over erythematous skin and apply friction parallel to the skin surface. Nikolsky sign is positive if this results

2018 American Society of Clinical Oncology Guidelines

39. Neonatal jaundice

· Consider: o TSB level o Gestation of baby o Age in hours of baby at time of testing 11 o Individual neurotoxicity risk factors 11,18 [refer to Section 7.2 Bilirubin induced neurologic dysfunction] Contraindications · Congenital erythropoietin porphyria (or family history) 70 o Very rare disorder o Porphyrins are photosensitisers causing injury to tissue (severe blistering and photosensitivity) when exposed to light 72 Side effects/ complications · Separation of mother and baby potentially resulting (...) of no clinical significance) · Blue light phototherapy—potential risk factor for melanocytic nevus development 73 Precautions · Medications: o Refer to Section 6 Medication use o Refer to an Australian pharmacopoeia for complete drug information regarding the use of medications and topical skin preparations during phototherapy o Concomitant use of photosensitising medications: § Usually only of concern after exposure to light in ultraviolet-A(UV-A) (320–400 nm) or UV-B (290–302nm) ranges § Insignificant UV

2018 Queensland Health

40. Targeted Immunomodulators for the Treatment of Moderate-to-Severe Plaque Psoriasis: Effectiveness and Value

, and psoralen with ultraviolet A (PUVA) treatment. Narrowband UVB is more effective than broadband UVB; both can be delivered at home. Psoralen, a photosensitizing drug, can be used orally or topically, as a bath, to the affected areas. Psoralen is associated with nausea, and PUVA is associated with increased squamous cell cancer and possibly melanoma; as such, UVB by far the most common form of phototherapy delivered in current clinical practice. A final form of phototherapy involves the use of excimer

2018 California Technology Assessment Forum

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>